Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 87 clinical trials
Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53 (BREAST TP53)

We did a prospective and retrospective cohort study of patients with a documented pathogenic or likely pathogenic variants of TP53 were identified using blood DNA colection and breast cancer

TP53
carcinoma
invasive carcinoma
  • 0 views
  • 29 Apr, 2022
  • 1 location
Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma

This study focuses on advanced lung and head and neck SCC tumours, with adjacent normal lung tissues. Biopsies will be performed in National University Health System, Singapore (NUHS) as part of participants' standard care. Patient blood was also required for extraction of cell free DNA (cfDNA) and genomic DNA (gDNA). …

TP53
cancer
metastatic squamous cell carcinoma
squamous cell carcinoma
  • 2 views
  • 07 Feb, 2022
  • 1 location
Registry of Li Fraumeni and Li Fraumeni Like Syndromes (ReLF)

ReLF is a retrospective and prospective registry, finalized to care and research. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc. This approach has been individuated in order …

  • 0 views
  • 08 Aug, 2022
p53 and Response to Preoperative Radiotherapy for T2 and T3 (PART1)

accepted that mutations in the TP53 gene represent a crucial defect in the apoptosis pathway. Radiation therapy is suggested to act via induction of apoptosis in irradiated cells. Therefore, it is expected

TP53
rectal neoplasm
adenocarcinoma
adenocarcinoma of rectum
metastasis
  • 8 views
  • 22 Apr, 2022
  • 1 location
Newer Therapeutic Targets in Head and Neck Cancers

survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA); cell-cycle control (e.g., CDKN2A and CCND1); cellular differentiation (e.g., NOTCH1); and Adhesion and invasion

EGFR
  • 0 views
  • 04 Jun, 2022
  • 1 location
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

therapies (e.g. ibrutinib, acalabrutinib) or combined immuno-chemotherapy regimens (e.g., fludarabine, cyclophosphamide, and rituximab for patients aged <65 years without del17p/TP53 mutations or

TP53
ibrutinib
fludarabine
platelet count
rituximab
  • 0 views
  • 01 Oct, 2021
  • 2 locations
The Culture of Ovarian Cancer Organoids and Drug Screening

The tumor organoids platform can provide the precise genetic information and phenotype, as well as the heterogeneity of the tumor, thus provide information on drug sensitivity specific to the patient.This is an exploratory research to see if organoids testing could help guide precision treatment for ovarian cancer(OC) patients.

cytoreductive surgery
carcinoma
cancer of the ovary
  • 0 views
  • 09 May, 2022
  • 1 location
Developing a Test for the Detection of Ovarian Cancer

The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, …

BRCA1
ovarian cancer
cancer of the ovary
BRCA2
cavity
  • 0 views
  • 10 May, 2022
  • 4 locations
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers

This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in patients with high-risk endometrial cancer. A liquid biopsy is a blood test that may be able to find cancer cells. Collecting and …

carcinosarcoma
  • 0 views
  • 26 Sep, 2021
  • 1 location
Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes

The aim of this study is to look for predisposing mutations in patients and relatives affected by AML and MDS with familial history of myeloid or, less frequently, lymphoid malignancies. Taking advantage of a next generation sequencing (NGS) platform, screening for known and unknown mutations potentially associated with the disease …

myeloid leukemia
thrombocytopenia
cancer
acute leukemia
  • 3 views
  • 01 May, 2022
  • 1 location